Rank #1: Immuno-Oncology Drug Development: Challenges & Next Steps
Ipilumumab/Nivo/Pembro challengesWhat can we learn from the development of sipuleucel-T that may be applicable for other therapeutic vaccines?Challenges with the following modalities: Checkpoints, Oncolytic Virus', Adoptive T-Cells, Cancer VaccinesBlinitumumabThe more interesting agents in late stage development now in immunotherapy and its promiseImmune related adverse eventsAdoptive cellular therapies, what is the most promising?Will IO become backbone therapies for cancer?What's the next set of assets that are going to come out?Promises in combination therapies?What can we expect next?
James Gulley, MD, PhD
Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute
Axel Hoos, MD, PhD, VP, Oncology R&D,GlaxoSmithKline
The Immuno-Oncology360° conference is scheduled for February 2-3, 2016 at the New York Academy of Medicine in NYC. For more information, please visit www.theconferenceforum.org.
Dec 21 2015
Rank #2: Reimagining Clinical Trials with Entrepreneur, Dr Ben Liu, CEO, Trialspark
Trialspark partners with doctors to create FDA compliant trial sites within their existing practices (like Airbnb), unlocking the 98% of patients and doctors not involved in trials today and democratizing access to research treatments. In this podcast discussion with Ben, we discuss how to reimagine clinical trials, entrepreneurism, the rise of Trialspark and reducing the barriers for patients and investigators.
Ben will be speaking at DPharm on September 26th in Boston with Dr Ulo Palm, SVP Global Drug Development Operations, Allergan on a case study to scale more efficient clinical trials.
For more information about Trialspark, visit www.trialspark.com
For more information about DPharm visit www.theconferenceforum.org
Producer: Valerie Bowling, Executive Director, Pharma Talk Radio and DPharm
Aug 17 2018
Rank #3: 2020 Immuno-Oncology 360° Summit Overview in 10 Minutes
The 6th annual IO360° Summit features the following plenaries:
Discovery/Preclinical ScienceImaging AspectsClinical OperationsBispecificsBusiness DevelopmentsCell & Gene TherapyTranslational ScienceEmerging BiomarkersIO Novel TechnologiesAI & Machine LearningClinical Developments
Dr Carl June, University of PennsylvaniaDr Arie Belldegrun, AllogeneDr Andrew Baum, CitiDr Crystal Mackall, Stanford University School of Medicine
Learn more at www.io360summit.com
Dec 04 2019
Rank #4: CAR-T Therapy: Optimization Through Engineering T-cells or Combinations
Save the date for IO Combinations 360° happening June 20-21, 2019 at the Wyndham Historic District Hotel, Philadelphia, PA and for IO360° happening February 26-28, 2020 at the Crowne Plaza Times Square in New York City.
May 02 2019
Rank #5: Improving T Cell Therapies via Next Generation Technologies
Dr Robert Ang, Neon TherapeuticsDr Usman "Oz" Azam, TmunityMichael Dombeck, Precision BioSciencesDr Aiman Shalabi, GSK
Save the date for the 6th annual IO360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com
Oct 17 2019
Rank #6: Connecting Employee-Centric Culture to Patient-Centric Culture
• What impact can engaged employees have on positioning the company as the preferred partner for patients and other collaborators?
• How can this be done? And for what purpose?
• How do you engage your employees and empower them to implement patient involvement strategies?
• Inspiring employees to make change?
The 4th annual Patients as Partners EU conference will take place on January 27-28, 2020.
To learn more about patient centricity in drug development and R&D and the Patients as Partners EU program, visit theconferenceforum.org.
Nov 01 2019
Rank #7: Cell & Gene Therapy Day Overview in 4 minutes
Key Topic Areas:
Landscape and Evolution to Marketplace: ProgressNew Scientific Frontiers in Cell Therapies for Solid TumorsCell Therapy Pivotal Developments for Solid TumorsCurrent and Future Innovations Toward GMP Manufacturing of CAR and TCR Engineered T CellsFDA Led Session on the Evolution of Regulatory Policy for Cell & Gene Therapy
Cell & Gene Therapy Day is available as an independent one day program with a luncheon and networking reception, to learn more please visit theconferenceforum.org
Alternatively, attendees can register for the three day IO360° program, which includes Cell & Gene Therapy Day. For more information on IO360°, please visit www.io360summit.com
Dec 04 2019
Rank #8: How to Align the Promise of Technology with the Patient Voice
The panel explores patient perspective on being monitored continuously and pharma perceptions of what patients want versus what patients really want.
Speakers: Cindy Geoghegan, Patient Advocate
Daniel Karlin, MD, CEO, Healthmode
Deanna Lennon, Director of Business Development, Medable Inc
Aug 22 2019
Rank #9: How to Innovate in the Drug Delivery Space
What does the innovation process look likeThe barrier to the innovation process and how to overcomethemSummary of disease spaceGood design and engineering practicesHow to salvage something that goes wrong?How do you find the unknown unknowns?Does it feel right?
Head of Drug Delivery, Cambridge Design Partnership
This talk was given at the 2018 Drug Delivery West Meeting.
Jun 23 2018
Rank #10: Partnering with Patients on Clinical Development Protocols
To learn more about the 7th annual Patients as Partners US conference taking place March 16-17, 2020 in Philadelphia, PA please visit theconferenceforum.org
Dec 20 2019
Rank #11: What are the Regulatory and Ethical Concerns of Integrating Care and Research?
Research and care or treatment are separate spheres in the regulatory and ethical worlds. What happens when they are brought together?Are there ethical barriers that need to be overcome to allow clinical research to be offered as an option as part of clinical care?What are the ethical issues that surround offering a patient the opportunity to consider enrolling in a clinical trial?What current efforts are underway to address these issues?
This session was presented at the Clinical Research as a Care Option (CRAACO) meeting in April 2018 in Cambridge, MA.
The 2019 CRAACO conference will take place April 29-30, 2019 in Raleigh-Durham, NA. Learn more here.
Feb 06 2019
Rank #12: Insights from Deal Trends: Betting on Tumor Immunology
Additional topics include:
Where are the next big paradigm shifts going to be?Where is the next great target that will supersize foundational checkpoint therapy?
Join us for the 6th annual IO360° conference on February 26-28, 2020 at the Crowne Plaza Times Square hotel in New York City.
To learn more about the event, please visit IO360 2020.
Aug 29 2019
Rank #13: A Patient Perspective on Living with Parkinson's Disease and the GDNF Trial
Ms Gosden will be the Keynote patient advocate speaker at the Patients as Partners EU conference taking place in London on January 27th and 28th and for more information, visit theconferenceforum.org.
Guest: Lesley Gosden, Patient Advocate
Host: Valerie Bowling, Producer, Pharma Talk Radio
For more information about the GDNF Trial: Reflections on the GDNF Trial
Aug 19 2019
Rank #14: Patients as Partners in Clinical Research EU 5 Min Upcoming Conf Summary
In a nutshell, Patient as Partners is the first conference in Europe dedicated to understanding how working with patients can drive greater clinical trial efficiencies throughout the entire medicines development process. It is ultimately about how to reduce risk in the development of hugely, costly clinical trials through working with patients. It is a wonderful opportunity for pharma and biotech and patient disease advocacy groups to come together and learn from each other.
The 2020 Summit is chaired by Claire Nolan, of Charities Research Involvement Group, GSK’s Andrew Garvey and Parexel’s Rosamund Round.
Our patient keynote guest is Lesley Gosden. Lesley is a Parkinson’s patient and advocate who participated in the GDNF clinical trial, which was featured on the BBC. For more information, visit the conferenceforum.org.
Jan 06 2020
Rank #15: How GSK Implemented Pivotal End-to-End Engagement Initiatives at Different Stage
• Creation of a framework and toolkit that builds on existing infrastructure
• Networks of champions and project leads
• Project planning
• Emerging best practices being shared throughout the organization
Dr Metcalf will also be joining the 6th annual Patients as Partners US program on March 11-12 at the Wyndham Philadelphia Historic District Hotel in Philadelphia where she leads a panel with patients and advocacy on Mapping Out the Patient Decision Making Journey. Patients as Partners US is the only conference that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. For more information visit www.theconferenceforum.org.
Jan 14 2019
Rank #16: Lessons Learned from a Veteran Biotech and Investor MD
You can join us at the 7th annual Chief Medical Officer Summit happening April 4-5, 2019 in Boston. To learn more visit theconferenceforum.org
Feb 04 2019
Rank #17: Progress and Future Outlook of Cancer Immunotherapy
Together Mr Graeber and Dr Gulley delved into the significance of this moment in science, what the progress has been and explore what is next on the horizon within immuno-oncology.
Both Dr Gulley and Mr Graeber will be presenting at the 5th annual IO360°, February 6-8 at The Crowne Plaza Times Square Hotel, NYC. For more information visit IO360°.
Jan 23 2019
Rank #18: Alzheimer’s Studies: Exploring Registries to Improve Enrollment & Trial Design
A Patient Registry can be very useful in identifying patients. A registry can also address the original problem statement about failed trials. A robust, living registry becomes a data pool from which we can improve both drug discovery, using probabilistic statistics and AI/ML to identify new drug candidates, and drug development, using simulators to predict likelihood of success in Phase 2 or 3.
In this podcast, we discuss major challenges facing developers of Alzheimer’s therapies and address patient registries and how they can improve enrollment and trial design. In this podcast, we will hear some details about the HealthyMindsRegistry, Synexushmr.com and the Protect Study Registry, Protectstudy.org.uk registry. For US and UK citizens over 50 who have not been diagnosed with dementia can participate in the registry on-line.
Dr Clive Ballard, Pro-Vice Chancellor and Executive Dean, University of Exeter, External partner in the AES HealthyMinds Registry (HMR)
Dr Heather Bryson, Director, Operational and Strategic Solutions at Accelerated Enrollment Solutions, (AES)
Host: Dr Julie Adams, Psychiatrist and Regional Medical Officer, PPD Biotech
Producer: Valerie Bowling, Executive Director, the Conference Forum
Jun 25 2019
Rank #19: Clinical update on AMG 420, an anti-BCMA BiTE®
This talk addresses the:
Summary of IND enabling preclinical studiesFirst-in-human trial designFirst-in-human trial data (safety, efficacy)
Save the date for the 6th annual Immuno-Oncology 360° Summit on February 26-28, 2020 at the Crowne Plaza Times Square in New York City. Learn more at www.io360summit.com
Nov 01 2019
Rank #20: How Digital Biomarker Innovation is Modernizing Clinical Endpoints
Understand what Digital Biomarker innovation means for the future of clinical development and potentially personalized healthcare.Be inspired to use mobile sensors technology in the context of clinical trials and beyond.Develop a detailed understanding of the underlying complexity to run such efforts and be able to plan for it.Understand how regulators are looking at these novel approaches.
Christian Gossens, PhD, MBA, Global Head Early Development Workflows, pRED, Informatics, Roche Pharmaceutical Research and Early Development (pRED)
The 9th annual DPharm conference with take place on September 17-18, 2019 in Boston, MA. Learn more at theconferenceforum.org.
Jul 31 2019